Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Enbridge Inc (ENB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Enbridge Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Enbridge Inc trades at $54.82 (market cap $118.96B). The key difference: Enbridge Inc is far larger — about 3× Alnylam Pharmaceuticals, Inc.'s market cap, and Enbridge Inc pays a 5.14% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | ENB | |
|---|---|---|
Market Cap | $39.89B | $118.96B |
Sector | Health | Energy |
52-Week High | $491.22 | $58.04 |
52-Week Low | $278.09 | $44.55 |
Enterprise Value | $38.15B | $199.76B |
Dividend Yield | — | 5.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Enbridge (ENB) trades at $54.66, up 0.13% on the day, with a neutral technical signal and mixed earnings history. The company reported strong revenue growth to $65.19B in 2025 and maintains a 10% net income margin. Recent news highlights its 5.1% dividend yield and AI-driven growth projects, while analyst consensus is evenly split between Buy and Hold ratings.
Outlook remains balanced with steady cash flow and dividend appeal offset by high debt levels and earnings volatility. Key opportunities include infrastructure expansion and high yield, while risks involve interest rate sensitivity and execution challenges in capital projects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →
